Sign Up Today and Learn More About Beam Therapeutics Stock
Invest in or calculate the value of your shares in Beam Therapeutics or other pre-IPO companies through EquityZen's platform.
Beam Therapeutics Stock
Developer of genome editing technologies.
About Beam Therapeutics Stock
Founded
2017
Headquarters
Cambridge, MA, US
Total Funding
87.0M
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Over half of the genetic errors associated with disease result from a single-letter change in the billions of bases that form the genome. In other cases, certain natural genetic variations in DNA are known to protect against disease. By changing a single letter – to eliminate errors or write in protective changes – in enough cells, base editing may help us prevent, modify, and even cure a wide range of diseases affecting patients’ lives.
Beam Therapeutics Press Mentions
Stay in the know about the latest news on Beam Therapeutics
Precision-Drug Startup Beam Therapeutics Raises $135 Million
Wall Streets Journal • Mar 06, 2019
Beam Therapeutics lasers in on $87m series A
Global University Venturing • May 15, 2018
Investors in Beam Therapeutics
Discover investors in Beam Therapeutics stock and explore their portfolio companies
Beam Therapeutics Management
Leadership team at Beam Therapeutics
Co-Founder
J. Keith Joung
Chief Scientific Officer
Giuseppe Ciaramella
Join now and verify your accreditation status to gain access to:
- Beam Therapeutics Current Valuation
- Beam Therapeutics Stock Price
- Beam Therapeutics Management
- Available deals in Beam Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Beam Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Beam Therapeutics Revenue and Financials
- Beam Therapeutics Highlights
- Beam Therapeutics Business Model
- Beam Therapeutics Risk Factors
- Beam Therapeutics Research Report from SACRA Research
Trading Beam Therapeutics Stock
How to invest in Beam Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Beam Therapeutics through EquityZen funds. These investments are made available by existing Beam Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Beam Therapeutics stock?
Shareholders can sell their Beam Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."